logo-header-min.png
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
November 22, 2022 07:00 ET | Marker Therapeutics
HOUSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
November 10, 2022 16:05 ET | Marker Therapeutics
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
September 13, 2022 07:00 ET | Marker Therapeutics
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
September 08, 2022 07:00 ET | Marker Therapeutics
HOUSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
August 11, 2022 16:22 ET | Marker Therapeutics
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
August 04, 2022 16:37 ET | Marker Therapeutics
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
May 13, 2022 07:00 ET | Marker Therapeutics
Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in...
logo-header-min.png
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
May 04, 2022 10:30 ET | Marker Therapeutics
HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
April 26, 2022 07:00 ET | Marker Therapeutics
HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based...
logo-header-min.png
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
March 17, 2022 17:45 ET | Marker Therapeutics
Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to...